文献速递胸部肿瘤

非小细胞肺癌奥希替尼治疗耐药后肿瘤微环境的变化

Tumour microenvironment changes after osimertinib treatment resistance in non-small cell lung cancer.
PubMed 文献 · Eur J Cancer · 2023-05-23

本研究探讨非小细胞肺癌奥希替尼耐药后肿瘤微环境重塑。基于RNA-seq的免疫浸润分析显示耐药时免疫评分、微环境评分和CD8+ T细胞显著下降,M0巨噬细胞增加;体外实验表明H1975OR细胞来源外泌体可被巨噬细胞摄取并驱动其向M2表型极化,极化M2巨噬细胞可减弱对肿瘤细胞增殖的抑制作用。外泌体miRNA-seq和蛋白质组学提示miR-1258-3p和miR-17-5p可能参与该相互作用。

要点

  • 奥希替尼耐药时免疫评分和微环境评分均显著下降(均P < 0.001)。
  • 耐药时CD8+ T细胞显著减少(P < 0.05),M0巨噬细胞显著增加(P < 0.01)。
  • H1975OR细胞外泌体驱动巨噬细胞向M2极化,减弱其对肿瘤增殖的抑制。

核心结论

  • 奥希替尼耐药时呈现免疫抑制环境,特征为T细胞浸润和活化减少而巨噬细胞浸润及M2极化增加。
  • 肿瘤来源外泌体可能介导这一相互作用。

研究设计与样本

  • 采用基于RNA-seq的肿瘤免疫浸润分析(TIMER 2.0)。
  • 进行流式细胞术和实时细胞分析以探索肿瘤细胞与免疫细胞的相互作用。
  • 通过miRNA-seq和无标记蛋白质组学分析外泌体。

主要发现

  • 与治疗前患者相比,奥希替尼耐药时免疫评分显著下降(P < 0.001)、微环境评分显著下降(P < 0.001)、CD8+ T细胞显著减少(P < 0.05),而M0巨噬细胞显著增加(P < 0.01)。
  • H1975OR细胞来源外泌体可被巨噬细胞摄取并驱动其向M2表型极化,极化的M2巨噬细胞可减弱对肿瘤细胞增殖的抑制作用。
  • 预激活的外周血单个核细胞对H1975OR细胞表现出更强的杀伤作用。
  • 与H1975OR来源外泌体或条件培养基共培养后,CD4+HLA-DR- T细胞减少而CD4+PD1+ T细胞增加。
  • 外泌体miRNA-seq和蛋白质组学分析显示miR-1258-3p和miR-17-5p可能参与该相互作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Growing evidence suggests that acquired resistance to targeted therapy in non-small cell lung cancer patients is linked to the mutual domestication between the tumour and its surrounding microenvironment. AIM: Our study aims to explore the remodelling of tumour microenvironment after osimertinib treatment resistance. METHODS: We took RNA-seq-based tumour immune infiltration analysis using the TIMER 2.0. We carried out flow cytometry assay and real-time cell analysis to explore the interaction between tumour cells and immune cells. In addition, we analysed exosomes via miRNA-seq and label-free proteomics. RESULTS: Immune infiltration estimation showed a significant decrease in the immune score (P < 0.001), microenvironment score (P < 0.001) and CD8+ T cells (P < 0.05), but an increase in M0 macrophages (P < 0.01) at osimertinib resistance compared to pre-treatment patients. It was demonstrated that exosomes from H1975OR cells could be taken up by macrophages and drove their polarisation towards the M2 phenotype, and the polarised M2 macrophages could reduce the inhibitory effect on tumour cell proliferation. Pre-activated peripheral blood mononuclear cells exhibited a more potent killing effect on H1975OR cells. We also detected a decrease in CD4+HLA-DR- T cells and an increase in CD4+PD1+ T cells after being co-cultured with H1975OR derived exosomes or conditioned medium. Further miRNA-seq and proteomics analysis of exosomes demonstrated that mir-1258-3p and miR-17-5p might participate in this interaction. CONCLUSIONS: An immunosuppressive environment, characterised by decreased T cell infiltration and activation, whereas increased macrophage infiltration and M2 polarisation, was identified at osimertinib resistance. This interaction may be carried out by tumour-derived exosomes.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Han R, Guo H, Shi J, et al. Tumour microenvironment changes after osimertinib treatment resistance in non-small cell lung cancer. Eur J Cancer. 2023. PMID: 37320935. doi:10.1016/j.ejca.2023.05.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。